Featured Article - ISSAR Pharma

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

October 28, 2021October 28, 2021root

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection A recent study published in the ‘Medicina’ Journal by the Multidisciplinary Digital Publishing Institute (MDPI), indicated that patients with…Continue readingPsoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection

Dermatology Featured Article Vitiligo

CXCL9: A biomarker for Vitiligo activity

October 12, 2021October 26, 2021root

CXCL9: A biomarker for Vitiligo activity A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a key biomarker for vitiligo activity and a significant predictor of…Continue readingCXCL9: A biomarker for Vitiligo activity

Bone and Joint Featured Article

ISSAR’s Novel Peptide Drug for Rheumatoid Arthritis

September 6, 2021September 8, 2021root

Rheumatoid Arthritis (RA) In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis (RA) was observed to be the 42nd highest…Continue readingISSAR’s Novel Peptide Drug for Rheumatoid Arthritis

Novoskin- Improved peptide for Vitiligo treatment

September 6, 2021September 29, 2021root

The global prevalence rate of vitiligo ranges between 0.4%-3%, affecting individuals of all ages, races, and genders. Vitiligo treatment market dynamics Combination treatment therapies contribute to the majority of the…Continue readingNovoskin- Improved peptide for Vitiligo treatment

ISSAR’s IS-217 for Inflammatory Bowel Diseases

September 6, 2021September 29, 2021root

Inflammatory Bowel Diseases (IBD) currently affect approximately 0.5% of the Western world’s population. The globally occurring cases increased from 3.7 million to over 6.8 million between the years 1990 to 2017.…Continue readingISSAR’s IS-217 for Inflammatory Bowel Diseases

ISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis

September 6, 2021September 8, 2021root

The global prevalence of psoriasis ranges between 0.09% to 11.14 %. Psoriasis affects >120 million worldwide, with no cure till date. The global psoriasis treatment market reached $20.19 billion in…Continue readingISSAR’s Dual Acting Anti-Psoriatic Molecule for Psoriasis

Dermatology Featured Article Psoriasis

Fixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris

July 26, 2021September 8, 2021root

A recent study published in the Journal of the European Academy of Dermatology and Venereology (JEADV), proposed that treatment of psoriasis vulgaris with calcipotriol (Cal) and betamethasone propionate (BD) foam…Continue readingFixed-Dose Combination of Calcipotriol and Betamethasone is Effective in Patients with Psoriasis Vulgaris

Dermatology Featured Article Vitiligo

A Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo

July 26, 2021September 8, 2021root

A recent study published in the Journal of Dermatologic Therapy suggested that a combination of excimer light and topical calcipotriol is effective in the treatment of acral vitiligo (vitiligo involving…Continue readingA Combination Treatment of Light Therapy and Topical Therapy is Effective in Acral Vitiligo

Dermatology Featured Article Vitiligo

I.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo

July 20, 2021September 8, 2021root

A recent study published in the Journal of Dermatology proposed that Intravenous Methylprednisolone Pulse therapy (IVMP) is a safe and effective treatment for progressive generalised vitiligo. The main aim of…Continue readingI.V. Methylprednisolone Pulse Therapy (IVMP) Is Safe and Effective for Progressive Generalised Vitiligo

Dermatology Featured Article Psoriasis

Systemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis

July 20, 2021September 8, 2021root

A recent study published in the Journal of the American Medical Association (JAMA), Dermatology reported that administration of systemic corticosteroids showed lesser rates of severe psoriasis flares in patients with…Continue readingSystemic Corticosteroids Less Likely to Cause Severe Flares in Patients With a History of Psoriasis

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.